首页 › 基金 › Tetragon Partners GP Ltd › AUTL
Tetragon Partners GP Ltd 对 AUTL 的持仓历史
AUTOLUS THERAPEUTICS LTD · 医疗保健
Tetragon Partners GP Ltd 在 Q3 2026 的 13F 申报中披露持有 AUTL(AUTOLUS THERAPEUTICS LTD)9,500,000 股,市值约 US$18.4M,约占其申报组合的 2.52%,在其申报持仓中市值排名第 5 位。 Tetragon Partners GP Ltd 最近 13 个申报季度中有 13 个季度披露了 AUTL 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Tetragon Partners GP Ltd 对 AUTL 的持仓演变
Tetragon Partners GP Ltd 于 Q3 2023 首次披露 AUTL 持仓:12,000,000 股(约 US$28.0M)。 该持仓在 Q4 2023 达到峰值 8,000,000 股,市值约 US$51.5M。 在 13 次申报中,Tetragon Partners GP Ltd 4 次增持、2 次减持、6 次保持不变。 最近一期申报(Q3 2026)显示持股 9,500,000 股、市值约 US$18.4M。 持仓曾出现大幅变动:Q4 2023 减持约 33% (随后一个季度股价基本持平)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 12.00M | $27.96M | 新进 |
| Q4 2023 | 8.00M | $51.52M | 减持 |
| Q1 2024 | 7.53M | $48.01M | 减持 |
| Q2 2024 | 8.00M | $27.84M | 增持 |
| Q3 2024 | 8.00M | $29.04M | 持有 |
| Q4 2024 | 8.25M | $19.39M | 增持 |
| Q1 2025 | 8.60M | $13.33M | 增持 |
| Q2 2025 | 9.50M | $21.66M | 增持 |
| Q3 2025 | 9.50M | $15.48M | 持有 |
| Q4 2025 | 9.50M | $18.91M | 持有 |
| Q1 2026 | 9.50M | $13.11M | 持有 |
| Q2 2026 | 9.50M | $15.20M | 持有 |
| Q3 2026 | 9.50M | $18.43M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 AUTL 与 13F 数据
AUTL(AUTOLUS THERAPEUTICS LTD)属于医疗保健行业。我们追踪的基金中还有 18 只申报持有 AUTL,申报仓位最大的包括:MAK CAPITAL ONE LLC (US$53.8M), Syncona Portfolio Ltd (US$32.3M), ARMISTICE CAPITAL, LLC (US$26.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 AUTL 的基金
- MAK CAPITAL ONE LLC 33.62M 股 · $53.79M · Q2 2026
- Syncona Portfolio Ltd 16.64M 股 · $32.28M · Q3 2026
- ARMISTICE CAPITAL, LLC 13.75M 股 · $26.68M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.45M 股 · $7.12M · Q2 2026
更多关于 Tetragon Partners GP Ltd
常见问题
How long has Tetragon Partners GP Ltd held AUTL?
Tetragon Partners GP Ltd has disclosed AUTL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Tetragon Partners GP Ltd's current position in AUTL?
As of Q3 2026, Tetragon Partners GP Ltd holds 9.50M shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $18.43M, representing 2.52% of its reported portfolio and ranking #5.
Has Tetragon Partners GP Ltd been buying or selling AUTL?
In the latest 13F filing (Q3 2026), Tetragon Partners GP Ltd held unchanged its position in AUTL. The position peaked in Q4 2023 at 8.00M shares.
Which other funds hold AUTL?
Other major institutional holders of AUTL include MAK CAPITAL ONE LLC, Syncona Portfolio Ltd, ARMISTICE CAPITAL, LLC, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.